A5021169621- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced Radiotherapy Techniques
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging and Pathology Studies
- Renal cell carcinoma treatment
- Medical Imaging Techniques and Applications
- Liver Disease and Transplantation
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- MRI in cancer diagnosis
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Effects of Radiation Exposure
- Radiation Therapy and Dosimetry
- Cancer, Hypoxia, and Metabolism
- Hepatitis B Virus Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Radiation Dose and Imaging
- Neuroblastoma Research and Treatments
- Organ Transplantation Techniques and Outcomes
- Photodynamic Therapy Research Studies
Northwestern University
2012-2024
Society of Interventional Radiology
2008-2023
American College
2023
Northwestern Memorial Hospital
2008-2020
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2007-2020
Anna Needs Neuroblastoma Answers
2020
American Association of Neurological Surgeons
2013
American College of Radiology
2013
American Society of Neuroradiology
2013
University Radiology
2009
Chemoembolization is one of several standards care treatment for hepatocellular carcinoma (HCC). Radioembolization with Yttrium-90 microspheres a novel, transarterial approach to radiation therapy. We performed comparative effectiveness analysis these therapies in patients HCC.We collected data from 463 who were treated locoregional (chemoembolization or radioembolization) over 9-year period. excluded not appropriate comparison and analyzed 245 (122 received chemoembolization 123...
This study was undertaken to present data from a phase 2 in which patients with unresectable hepatocellular carcinoma (HCC) and without portal vein thrombosis underwent radioembolization Yttrium (90Y) microspheres. Patients treated were stratified by Okuda, Child-Pugh, baseline bilirubin, tumor burden, Eastern Cooperative Oncology Group (ECOG), presence of cirrhosis (PVT) (none, branch, main). Clinical biochemical obtained at 4-week intervals following treatment for up 6 months. Tumor...
Yttrium‐90 microsphere brachytherapy of the liver exploits distinctive features anatomy to treat malignancies with beta radiation and is gaining more wide spread clinical use. This report provides a general overview assists treatment team in creating local practices provide safe efficient patient treatment. Suggestions for future improvements are incorporated basic rationale therapy currently used procedures. Imaging modalities utilized their respective quality assurance discussed. General...
We present the correlation between radiologic and pathologic findings in HCC patients who underwent radioembolization with yttrium-90 ((90)Y) microspheres prior to resection or transplantation. Thirty-five a total of 38 lesions liver explantation after (90)Y were studied. Imaging surrogates following treatment evaluated; explants examined for assessment necrosis by pathology. The histologic treated was analyzed. Twenty-three (61%) target showed complete necrosis. All demonstrated some degree...
Purpose: To prospectively evaluate the safety, efficacy, and survival of patients with chemorefractory liver metastases who have been treated yttrium 90 (90Y) glass microspheres. Materials Methods: Institutional review boards from two institutions approved HIPAA-compliant study; all provided informed consent. One hundred thirty-seven underwent 225 administrations 90Y microspheres by using intraarterial infusion. Primary sites (origins) included colon, breast, neuroendocrine, pancreas, lung,...
Objective: To assess the incidence of clinical and imaging radiation pneumonitis (RP) in a cohort patients treated with >30 Gy cumulative lung dose (CLD) using Y90 microspheres. Materials Methods: Four hundred three were microspheres during 4-year period. Of these, 58 received CLD. Patients followed for toxicities suggestive or RP. Toxicities graded Radiation Therapy Oncology Group/European Organisation Research Treatment Cancer Late Morbidity Scoring Schema. also survival from time first...
Background & AimsIt is not clear whether survival times of patients with hepatocellular carcinoma (HCC) are associated their response to therapy. We analyzed the association between tumor and HCC who were treated locoregional therapies (LRTs) (chemoembolization radioembolization).MethodsPatients received LRTs over a 9-year period (n = 463). Patients metastases, portal venous thrombosis, or had transplants excluded; 159 Child–Pugh B7 lower analyzed. Response (based on European Association for...
Radioembolization with 90Y microspheres represents a novel transarterial radiation treatment for liver tumors. The purpose of this pilot study was to evaluate the findings postimplantation PET/CT glass microspheres.Three patients hepatocellular carcinoma and 2 metastases (1 neuroendocrine, 1 colorectal) underwent after radioembolization. Four imaging at mo assess response confirm findings; patient 4 d implantation. Patients were followed adverse events.Standard enabled localization all...